Home › Phases › Approved

Approved (57 companies)

Companies with at least one active program at Approved.

Ticker Company Therapeutic areas Approved programs Lead stage Mkt cap Programs
ADCT ADC Therapeutics Oncology 1 Approved $172M 5
ADMA Adma Biologics ImmunologyInfectious Disease Rare 3 Approved $3.02B 4
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 3 Approved $1.79B 7
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 3 Approved $111M 10
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 2 Approved $1.36B 9
ARDX Ardelyx GI/HepatologyRenal 2 Approved $799M 4
ARVN Arvinas NeurologyOncology Rare 1 Approved $447M 10
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $290M 12
AXSM Axsome Therapeutics Neurology Rare 4 Approved $7.15B 15
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 2 Approved $1.93B 4
CHRS Coherus Oncology Oncology 1 Approved $74.0M 5
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 1 Approved — 6
ENTA Enanta Pharmaceuticals DermatologyImmunology+2 1 Approved $253M 8
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 10 Approved $1.84B 17
EXEL Exelixis CardiovascularOncology 6 Approved $16.7B 23
FBIO Fortress Biotech DermatologyHematology+4 Rare 5 Approved $61.4M 16
GERN Geron Oncology 1 Approved $644M 3
HRMY Harmony Biosciences MetabolicNeurology Rare 4 Approved $1.94B 17
HROW Harrow Ophthalmology Rare 9 Approved $1.11B 15
IBRX ImmunityBio Infectious DiseaseOncology 1 Approved $6.66B 17
IMCR Immunocore DermatologyInfectious Disease+2 1 Approved $1.44B 12
INSM Insmed CardiovascularImmunology+3 Rare 5 Approved $26.7B 15
IVVD Invivyd Infectious Disease 1 Approved $152M 5
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 13 Approved $4.49B 29
KURA Kura Oncology MetabolicOncology 1 Approved $688M 13
LEGN Legend Biotech Oncology Rare 1 Approved $3.12B 17
LENZ LENZ Therapeutics Ophthalmology 1 Approved $110M 1
LQDA Liquidia CardiovascularImmunology+1 Rare 3 Approved $5.11B 9
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 1 Approved $1.54B 5
MIST Milestone Pharmaceuticals Cardiovascular 1 Approved $51.4M 2
NRXP NRX Pharmaceuticals Neurology Rare 1 Approved $109M 11
OMER Omeros HematologyNeurology+2 Rare 1 Approved $1.04B 6
IRD Opus Genetics Ophthalmology Rare 2 Approved $391M 12
OTLK Outlook Therapeutics Ophthalmology 1 Approved $87.9M 3
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 2 Approved $8.14B 12
RLAY Relay Therapeutics DermatologyOncology Rare 1 Approved $3.64B 4
REPL Replimune Group Oncology 1 Approved $1.87B 5
RVMD Revolution Medicines Oncology 1 Approved $35.2B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare 4 Approved $8.08B 14
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 1 Approved $236M 4
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 4 Approved $1.58B 11
SCYX Scynexis Infectious DiseaseRenal Rare 1 Approved $28.4M 5
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 3 Approved $822M 7
TLX Telix Pharmaceuticals Oncology 4 Approved $3.01B 25
TGTX Tg Therapeutics Neurology Rare 1 Approved $9.48B 6
TVTX Travere Therapeutics MetabolicRenal Rare 3 Approved $4.91B 7
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 7 Approved $1.70B 10
QURE uniQure HematologyMetabolic+1 Rare 1 Approved $1.46B 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 8 Approved $230M 27
VERA Vera Therapeutics Infectious DiseaseRenal Rare 1 Approved $1.89B 6
VSTM Verastem Oncology 1 Approved $934M 5
VRCA Verrica Pharmaceuticals DermatologyOncology Rare 1 Approved $53.9M 4
VRDN Viridian Therapeutics ImmunologyOphthalmology 1 Approved $3.41B 7
XFOR X4 Pharmaceuticals — 1 Approved $316M 2
XNCR Xencor ImmunologyNeurology+1 Rare 2 Approved $2.59B 28
XERS Xeris Biopharma MetabolicNeurology Rare 3 Approved $3.07B 4
ZYME Zymeworks OncologyRespiratory 3 Approved $1.78B 12